The infamous, and controversial, article on the New England Journal of Medicine has rekindled the polemics about whose machine is giving less radiation dose!
I share the disdain of my esteemed colleague Arun Singh against “blatantly inaccurate†numbers spread by “salespeople with limited knowledge and understandingâ€. Especially when the numbers concern radiation measurements, radiation absorbed dose, and radiation (estimated) risk and detriment, topics (particularly the latter) upon which even experts and specialists disagree more often than not.
However, I urge Arun not to fall into the trap of the “my CBCT gives less dose than your CBCT†contest (or the contest on other supposedly comparable performance) … in a forum where the initiative should primarily be left to the clinical users rather than to the representatives of the industry. Since statements on specific products have been made, however, I feel myself compelled (this time only) to counter-comment at least on the subject of radiation dose.
The bottom line is that this (sterile) debate about radiation dose comparison between different CBCTs distracts the attention from the really important points, that is:
(1) In all circumstances, radiation dose from any CBCT machine is at least one order of magnitude smaller than with conventional CT machines, yet with pretty comparable diagnostic yield (as pointed out already in many comments).
(2) We talk here (and with panoramic machines, and with intraoral x-rays) of vanquishing small effective dose, so much so that its very measurement is controversial, even more so is the risk associated to it, which is always merely presumed and estimated (not directly measured) using a conventional and arbitrary model, that was originally devised for a different scope and context (protection of the general population from the consequences of the nuclear energy industry).
Ironically, producing (and imparting) LESS radiation dose (or dose rate) is technically NEVER a problem, rather the opposite is true. The challenge is to achieve diagnostically-proper image quality with a given radiation dose – or properly balance the imparted radiation dose with the achievable diagnostic results.
As said, the measurement of such (effective) doses and the interpretation of the detriment are pretty difficult. To date the works from John Ludlows et al. offer the only comprehensive data reported in scientific literature by independent researchers for dental CBCT machines, but also their interpretation is fraught with pitfalls. For instance, the numbers can change by a factor two depending upon what ICRP guideline is adopted. These difficulties contribute to the ambiguities of sometimes comparing apples with oranges, into which the “salespeople with limited knowledge and understanding†thrive.
While the latest published (or publicly disclosed) studies that I know of (from Ludlow et al.) still show NewTom 3G at the bottom of the dose ranking (and below iCat), a direct comparison of the numbers (whatever they mean) for iCat or Galileos to those for NewTom 3G 12†is improper, because the Field of View and imaged volume with the latter is significantly larger than with the former two. A fair comparison might be with NewTom 3G in 9†FOV mode, that has a smaller imaged volume comparable to that of iCat and Galileos, but neither Ludlow nor anyone else (I believe) has measured and/or published it. It is evident that the dose in 9†mode should be less than in 12†mode.
As to the dose imparted by NewTom VG, I can guarantee that it uses essentially the same technique factors (kV, mAs, distances) as in NewTom 3G, but the FOV is smaller, therefore the effective absorbed dose with NewTom VG must be even lower than with NewTom 3G 12â€.
Roberto Molteni
Executive Vice President, Technology
AFP Imaging / NewTomDental / QR